iShares MSCI Japan ETF vs 22nd Century Group Inc — how do they compare? iShares MSCI Japan ETF trades at $97.86 (market cap $23.87B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: iShares MSCI Japan ETF is far larger — about 38396.6× 22nd Century Group Inc's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and 22nd Century Group Inc for 32 Days on average.
| EWJ | XXII | |
|---|---|---|
Market Cap | $23.87B | $621.67K |
Volume | 5,412,820 | 45,625 |
Sector | Broad Market / Factor | Consumer Staples |
52-Week High | $99.32 | $483.00 |
52-Week Low | $78.36 | $0.80 |
Typical Hold Time | 56 Days | 32 Days |
Enterprise Value | — | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.32, down 1.02% on the day. Technical indicators show a neutral overall signal with mixed moving averages and oscillators. Recent news highlights Japan's monetary policy uncertainty as the Bank of Japan navigates rate hikes amid fiscal stimulus concerns. The ETF remains positioned within a tight trading range between $96 support and $99 resistance levels.
Outlook remains cautious as Japan faces monetary tightening headwinds while maintaining fiscal stimulus. Investment opportunity exists in Japan's AI and semiconductor exposure, though currency volatility and rising bond yields present near-term risks. The neutral technical stance suggests limited directional momentum pending clearer policy signals from Japanese authorities.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →